Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class

Journal of Medicinal Chemistry

Volumn 41, Issue 18, 1998, Pages 3467-3476

  Turner, Steve R ^a   Strohbach, Joseph W ^a   Tommasi, Ruben A ^b   Aristoff, Paul A ^a   Johnson, Paul D ^a   Skulnick, Harvey I ^a   Dolak, Lester A ^a   Seest, Eric P ^a   Tomich, Paul K ^a   Bohanon, Michael J ^a   Horng, Miao Miao ^a   Lynn, Janet C ^a   Chong, Kong Teck ^a   Hinshaw, Roger R ^a   Watenpaugh, Keith D ^a   Janakiraman, Musiri N ^a   Thaisrivongs, Suvit ^a  

^a PFIZER INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PHENPROCOUMON; PROTEINASE INHIBITOR; TIPRANAVIR; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR INTERACTION; NONHUMAN; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; CELL LINE, TRANSFORMED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYDROGEN BONDING; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PYRIDINES; PYRONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12944322516     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9802158     Document Type: Article

References (36)

1. Blundell, T. L.; Lapatto, R.; Wilderspin, A. F.; Hemmings, A. M.; Hobart, P. M.; Danley, D. E.; Whittle, P. J. The 3-D Structure of HIV-1 Protease and the Design of Antiviral Agents for the Treatment of AIDS. Trends Biol. Sci. 1990, 15, 425-430.
2. Debouck, C.; Metcalf, B. W. Human Immunodeficiency Virus Protease: A Target for AIDS Therapy. Drug. Dev. Res. 1990, 21, 1-17.
3. Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314.
4. Meek, T. D. Inhibitors of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98.
5. Thaisrivongs, S. Chapter 14. HIV Protease Inhibitors. Annu. Rep. Med. Chem. 1994, 29, 133-144.
6. Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124.
7. Plattner, J. J.; Norbeck, D. W. Obstacles to Drug Development from Peptide Leads. In Drug Discovery Technologies; Clark, C. R., Moos, W. H., Eds.; Ellis Horwood Ltd.: Chichester, 1990; Chapter 5, pp 92-126.
8. Martin, J. A. Recent Advances in the Design of HIV Protease Inhibitors. Antiviral Res. 1992, 17, 265-278.
9. Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E., Saldivar, A.; Vasavanonda, S.; Marsh, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenyl-hexane-3,4-diol. J. Med. Chem. 1993, 36, 320-330.
10. Kempf, D. J.; Marsh, K. C.; Fino, L. C.; Bryant, P.; Craig-Kennard, A.; Sham, H. L.; Zhao, C.; Vasavanonda, S.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Green, B. E.; Herrin, T.; Norbeck, D. W. Design of Orally Bioavailable, Symmetry-based Inhibitors of HIV Protease. Bioorg. Med. Chem. 1994, 2, 847-858.
11. Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X.-P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
12. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. L; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Vastag, K.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100.
13. Lam, P. Y.-S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek. J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Vitanen, S. Rational Design of Potent, Bioavailable, Non-peptide Cyclic Urea as HIV Protease Inhibitors. Science 1994, 263, 380-384.
14. Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Erickson-Vitanen, S.; Grubb, M. F.; Quon, C. Y.; Huang, S.-M. A Pharmacokinetic Evaluation of HIV Protease Inhibitors, Cyclic Ureas, in Rats and Dogs. Biopharm. Drug Disp. 1994, 15, 535-544.
15. Getman, D. P.; DeCrescenzo, G. A.; Heintz, R. M.; Reed, K. L.; Talley, J. J.; Bryant, M. L.; Clare, M.; Houseman, K. A.; Marr, J. J.; Mueller, R. A.; Vazquez, M. L.; Shieh, H.-S.; Stallings, W. C.; Stegeman, R. A. Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere. J. Med. Chem. 1993, 36, 288-291.
16. Bryant, M. HIV Protease Inhibitors: Action to Efficacy. Inhibitor SC-55389a presented at Session 46 (I) at the 34th ICAAC, Orlando, FL, 1994.
17. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
18. Kaldor, S. W.; Kalish, V. J.; Davies, J. F., II; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease. J. Med. Chem. 1997, 40, 3979-3985.
19. Mimoto, T.; Imai, J.; Kisanuki, S.; Enomoto, H.; Hattori, N.; Akaju, K.; Kiso, Y. Kynostatin KNI-227 and -272, Highly Potent Anti-HIV Agents: Conformationally Constrained Tripeptide Inhibitors of HIV Protease Containing Allophenylnorstatine. Chem. Pharm. Bull. 1992, 40, 2251-2253.
20. Thaisrivongs, S.; Tomich, P. K.; Watenpaugh, K. D.; Chong, K.-T.; Howe, W. J.; Yang, C.-P.; Strohbach, J. W.; Turner, S. R.; McGrath, J. P.; Bohanon, M. J.; Lynn, J. C.; Mulichak, A. M.; Spinelli, P. A.; Hinshaw, R. R.; Pagano, P. J.; Moon, J. B.; Ruwart, M. J.; Wilkinson, K. F.; Rush, B. D.; Zipp, G. L.; Dalga, R. J.; Schwende, F. J.; Howard, G. M.; Padbury, G. E.; Toth, L. N.; Zhao, Z.; Koeplinger, K. A.; Kakuk, T. J.; Cole, S. L.; Zaya, R. M.; Piper, R. C.; Jeffrey, P. Structure-Based Design of HIV Protease Inhibitors: 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Nonpeptidic Inhibitors. J. Med. Chem. 1994, 37, 3200-3204.
21. Skulnick, H. I.; Johnson, P. D.; Howe, W. J.; Tomich, P. K.; Chong, K.-T.; Watenpaugh, K. D.; Janakiraman, M. N.; Dolak, L. A.; McGrath, J. P.; Lynn, J. C.; Horng, M.-M.; Hinshaw, R. R.; Zipp, G. L.; Ruwart, M. J.; Schwende, F. J.; Zhong, W.-Z.; Padbury, G. E.; Dalga, R. J.; Shiou, L.; Possert, P. I.; Rush, B. D.; Wilkinson, K. F.; Howard, G. M.; Toth, L. N.; Williams, M. G.; Kakuk, T. J.; Cole, S. L.; Zaya, R. M.; Thaisrivongs, S.; Aristoff, P. A. Structure-Based Design of Sulfonamide Substituted Nonpeptidic HIV Protease Inhibitors. J. Med. Chem. 1995, 38, 4968-4971.
22. Thaisrivongs, S.; Watenpaugh, K. D.; Howe, W. J.; Tomich, P. K.; Dolak, L. A.; Chong, K.-T.; Tomich, C.-S. C.; Tomasselli, A. G.; Turner, S. R.; Strohbach, J. W.; Mulichak, A. M.; Janakiraman, M. N.; Moon, J. B.; Lynn, J. C.; Horng, M.-M.; Hinshaw, R. R.; Curry, K. A.; Rothrock, D. J. Structure-Based Design of Novel HIV Protease Inhibitors: Carboxamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Nonpeptidic Inhibitors. J. Med. Chem. 1995, 38, 3624-3637.
23. Thaisrivongs, S.; Romero, D. L.; Tommasi, R. A.; Janakiraman M. N.; Strohbach, J. W.; Turner, S. R.; Biles, C.; Morge, R. R.; Johnson, P. D.; Aristoff, P. A.; Tomich, P. K.; Lynn, J. C.; Horng M.-M.; Chong, K.-T.; Hinshaw, R. R.; Howe, W. J.; Finzel, B. C.; Watenpaugh, K. D. Structure-Based Design of HIV Protease Inhibitors: 5,6-Dihydro-4-hydroxy-2-pyrones as Effective, Nonpeptidic Inhibitors. J. Med. Chem. 1996, 39, 4630-4642.
24. Thaisrivongs, S.; Skulnick, H. I.; Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Johnson, P. D.; Aristoff, P. A.; Judge, T. M.; Gammill, R. B.; Morris, J. K.; Romines, K. R.; Chrusciel, R. A.; Hinshaw, R. R.; Chong, K.-T.; Tarpley, W. G.; Poppe, S. M.; Slade, D. E.; Lynn, J. C.; Horng, M.-M.; Tomich, P. K.; Seest, E. P.; Dolak, L. A.; Howe, W. J.; Howard, G. M.; Schwende, F. J.; Toth, L. N.; Padbury, G. E.; Wilson, G. J.; Shiou, L.; Zipp, G. L.; Wilkinson, K. F.; Rush, B. D.; Ruwart, M. J.; Koeplinger, K. A.; Zhao, Z.; Cole, S.; Zaya, R. M.; Kakuk, T. J.; Janakiraman, M. N.; Watenpaugh, K. D. Structure-Based Design of HIV Protease Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Nonpeptidic Inhibitors. J. Med. Chem. 1996, 39, 4349-4353.
25. Jubert, C.; Knochel, P. Preparation of Polyfunctional Nitro Olefins and Nitroalkanes Using the Copper-Zinc Reagents RCu-(CN)ZnI. J. Org. Chem. 1992, 57, 5431-5438.
26. Judge, T. M.; Phillips, G.; Morris, J. K.; Lovasz, K. D.; Romines, K. R.; Luke, G. P.; Tulinsky, J.; Tustin, J. M.; Chrusciel, R. A.; Dolak, L. A.; Mizsak, S. A.; Watt, W.; Morris, J.; Vander Velde, S. L.; Strohbach, J. W.; Gammill, R. B. Asymmetric Syntheses and Absolute Stereochemistry of 5,6-Dihydro-α-pyrones, A New Class of Potent HIV Protease Inhibitors. J. Am. Chem. Soc. 1997, 119, 3627-3628. Stereoselective pilot scale syntheses have also been developed (J. Org. Chem., in press).
27. Judge, T. M.; Phillips, G.; Morris, J. K.; Lovasz, K. D.; Romines, K. R.; Luke, G. P.; Tulinsky, J.; Tustin, J. M.; Chrusciel, R. A.; Dolak, L. A.; Mizsak, S. A.; Watt, W.; Morris, J.; Vander Velde, S. L.; Strohbach, J. W.; Gammill, R. B. Asymmetric Syntheses and Absolute Stereochemistry of 5,6-Dihydro-α-pyrones, A New Class of Potent HIV Protease Inhibitors. J. Am. Chem. Soc. 1997, 119, 3627-3628. Stereoselective pilot scale syntheses have also been developed (J. Org. Chem., in press).
28. Thaisrivongs, S.; Janakiraman, M. N.; Chong, K.-T.; Tomich, P. K.; Dolak, L. A.; Turner, S. R.; Strohbach, J. W.; Lynn, J. C.; Horng, M.-M.; Hinshaw, R. R.; Watenpaugh, K. D. Structure-Based Design of Novel HIV Protease Inhibitors: Sulfonamide-Containing 4-Hydroxyeoumarins and 4-Hydroxy-2-pyrones as Potent Non-Peptidic Inhibitors. J. Med. Chem. 1996, 39, 2400-2410.
29. Cheng, Y.-S. E.; Yin, F. H.; Foundling, S.; Blomstrom, D.; Kettner, C. A. Stability and Activity of Human Immunodeficiency Virus Protease: Comparison of the Natural Dimer with a Homologous, Single-Chain Tethered Dimer. Proc. Natl. Acad. Sci. U.S.A. 1990, 88, 9660-9664.
30. Mildner, A. M.; Rothrock, D. J.; Leone, J. W.; Bannow, C. A.; Lull, J. M.; Reardon, I. M.; Sarcich, J. L.; Howe, W. J.; Tomich, C. C.; Smith, C. W.; Heinrikson, R. L.; Tomasselli, A. G. The HIV-1 Protease as Enzyme and Substrate: Mutagenesis of Autolysis Sites and Generation of a Stable Mutant with Retained Kinetic Properties. Biochemistry 1994, 33, 9405-9413.
31. We thank Professor Ben M. Dunn, University of Florida, Gainesville, FL, for the aspartyl protease assay results.
32. Markowitz, M.; Mo, H.; Kempf, D. J.; Norbeck, D. W.; Bhat, T. N.; Erickson, J. W.; Ho, D. D. Selection and Analysis of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-538, a Novel Protease Inhibitor. J. Virology 1995, 69, 701-706.
33. Poppe, S. M.; Slade, D. E.; Chong, K.-T.; Hinshaw, R. R.; Pagano, P. J.; Markowitz, M.; Ho, D. D.; Mo, H.; Gorman, R. R., III; Dueweke, T. J.; Thaisrivongs, S.; Tarpley, W. G. Antiviral Activity of the Dihydropyrone PNU-140690, a New Nonpeptidic Human Immunodeficienty Virus Protease Inhibitor. Antimicrob. Agents Chemother. 1997, 41, 1058-1063.
34. Wathen, W. M. In vitro evaluation of U-140135 and U-140690 protease inhibitors against a panel of HIV-1 clinical isolates (contracted study with SRA Technologies), unpublished results; experiments performed according to the procedure of Japour, A. J.; Mayers, D. L.; Johnson, V. A.; Kuritzkes, D. R.; Beckett, L. A.; Arduino, J.-M.; Lane, J.; Black, R. J.; Reichelderfer, P. S.; D'Aquila, R. T.; Crumpacker, C. S. Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates. Antimicrob. Agents Chemother. 1993, 37, 1095-1101.
35. Wathen, W. M. In vitro evaluation of U-140135 and U-140690 protease inhibitors against a panel of HIV-1 clinical isolates (contracted study with SRA Technologies), unpublished results; experiments performed according to the procedure of Japour, A. J.; Mayers, D. L.; Johnson, V. A.; Kuritzkes, D. R.; Beckett, L. A.; Arduino, J.-M.; Lane, J.; Black, R. J.; Reichelderfer, P. S.; D'Aquila, R. T.; Crumpacker, C. S. Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates. Antimicrob. Agents Chemother. 1993, 37, 1095-1101.
36. Borin, M. T.; Carlson, G. F.; Wang, Y.; Brewer, J. E.; Daenzer, C. L.; Baldwin, J. R.; Li, H. Single-dose safety, tolerance, and pharmacokinetics of PNU-140690, a new HIV protease inhibitor, in healthy volunteers. 37th ICACC, Toronto, Ontario, Sept 28-Oct 1, 1997.